Clinical Trial Update: Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial of ponatinib in patients with resistant chronic phase chronic myeloid leukemia to characterize efficacy and safety across multiple do…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Ponatinib (Iclusig) (ponatinib)

Snippet

Sponsor: Takeda | Conditions: Myeloid Leukemia, Chronic, Chronic Phase | Phase 2 | Status: COMPLETED | Results posted: 2021-06-14